Indivior stock holds firm as Supernus merger and higher 2026 EBITDA outlook reshape the story
Published on 08/22/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior (GB00BYZ0C031) stock is trading in the low teens in late August 2026 as investors digest a proposed merger with Supernus Pharmaceuticals and a higher 2026 adjusted EBITDA outlook in the range of $700 million to $740 million per recent earnings commentary on August 21, 2026. A fresh valuation discussion on August 22, 2026 highlights that the shares change hands at $36.87 in one ADR-focused narrative while another quote page shows a recent close of $11.73, underscoring the dual perspectives on Indivior's valuation and currency context.
Market snapshot and valuation context
A recent quote overview updated on August 22, 2026 shows Indivior at a previous close of $11.73, with the session opening at $11.58 and trading in a day's range between $11.37 and $11.65, framing a relatively tight intraday band for the stock as of that date [https://ca.finance.yahoo.com/quote/INDV/]. This same overview indicates that the bid is $11.37 and the ask is $11.43, suggesting modest liquidity around the current price region for Indivior's listing [https://ca.finance.yahoo.com/quote/INDV/]. In a separate valuation piece dated August 22, 2026, Indivior Pharmaceuticals is discussed at a share price of $36.87 with a one-month share price return that declined 8.85 percent and a one-year total shareholder return of 51.60 percent, highlighting a pullback in the short term against a strong longer-term performance [https://finance.yahoo.com/markets/stocks/articles/indivior-pharmaceuticals-indv-could-30-021141779.html].
The same August 22, 2026 valuation discussion notes that, compared with the last close at $36.87, a fair value estimate is placed at $53.00 using a discount rate of 7.11 percent, which implies a discount of roughly 30 percent to this modeled intrinsic value [https://finance.yahoo.com/markets/stocks/articles/indivior-pharmaceuticals-indv-could-30-021141779.html]. Another analysis on August 21, 2026 points out that Indivior shares trade at 3.29 times forward 12-month sales per share, compared with 2.02 times for a relevant peer sub-industry and a five-year median valuation of 2.7 times for Indivior itself, suggesting that the stock now sits at a premium to both peers and its own historical average multiple [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689]. For investors, this mix of a premium sales multiple and a discounted fair-value model underlines the debate over how much of the company’s improving fundamentals and strategic moves is already reflected in the price.
Q2 2026 results highlight Sublocade growth
A second-quarter 2026 earnings analysis dated August 21, 2026 underscores that Indivior's key long-acting buprenorphine product Sublocade generated $253 million in second-quarter 2026 revenues, representing a 21 percent year-over-year increase in the period [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. In the same quarter, U.S. dispense volume for Sublocade increased 18 percent and new patient starts reached a record 32,816, indicating that patient penetration is still expanding alongside revenue growth [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. These dynamics show that Indivior is not only selling more product but also bringing a growing cohort of new patients into treatment.
The Q2 2026 commentary further notes that adjusted operating expenses fell 33 percent year over year to $112 million, reflecting a significant cost reset in the period [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. As a result, adjusted EBITDA increased 111 percent to $186 million in the second quarter as Indivior combined higher revenues with leaner spending, showing a powerful operating leverage effect [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. Cash and investments also rose to $249 million at the end of the quarter from $201 million on March 31, 2026, reinforcing the balance sheet as the company pursues its growth and transaction plans [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ].
Higher 2026 EBITDA guidance and Supernus merger plan
Following these second-quarter 2026 results, Indivior raised its standalone 2026 adjusted EBITDA outlook to a range of $700 million to $740 million, signaling greater confidence in operating leverage and cost discipline as the year progresses [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689]. A separate August 21, 2026 analysis reiterates that this higher standalone adjusted EBITDA outlook provides a baseline for evaluating potential transaction effects from the planned combination with Supernus, effectively giving investors a clearer reference point for Indivior’s profitability before any deal synergies are realized [https://www.zacks.com/stock/news/2978608/indiviors-supernus-merger-could-broaden-its-growth-engine-in-2026]. The same discussion notes that the updated 2026 adjusted EBITDA range of $700 million to $740 million is framed explicitly as a standalone outlook, which reinforces the message that management expects meaningful earnings power even without merger benefits [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689].
In parallel, an article dated August 21, 2026 describes how the proposed merger with Supernus Pharmaceuticals would broaden Indivior's central nervous system pipeline and create a pro forma company expected to generate approximately $2.2 billion in annual revenues and $888 million in adjusted EBITDA [https://finance.yahoo.com/healthcare/articles/indiviors-supernus-merger-could-broaden-164000641.html]. The same analysis notes that Indivior's raised standalone 2026 adjusted EBITDA outlook to $700 million to $740 million sits alongside the pro forma combination’s $888 million adjusted EBITDA expectation, suggesting that incremental synergies and scale benefits could lift profitability beyond Indivior’s already upgraded plan [https://finance.yahoo.com/healthcare/articles/indiviors-supernus-merger-could-broaden-164000641.html]. This proposed deal is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals and customary closing conditions, which means transaction risk and timeline execution will be key watchpoints for investors through the back half of the year [https://finance.yahoo.com/healthcare/articles/indiviors-supernus-merger-could-broaden-164000641.html].
Consensus targets and relative valuation
One recent overview cited on August 21, 2026 notes that Indivior stock carries a consensus target price of $45.17, which implies potential upside of 19.55 percent from the current trading region highlighted in that analysis [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689]. In that same context, the stock's forward 12-month sales multiple of 3.29 times compares with 2.02 times for a relevant peer group sub-industry and a five-year median of 2.7 times for Indivior itself, indicating that the shares trade at a valuation premium both to peers and to their own historical norm [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689]. For investors, the combination of a premium valuation multiple and a consensus target that still suggests double-digit percentage upside reflects a delicate balance between growth expectations and perceived risk.
Another valuation-focused article on August 22, 2026 argues that Indivior Pharmaceuticals could be undervalued by about 30 percent based on a modeled fair value of $53.00 relative to the contemporaneous share price of $36.87, using a discount rate of 7.11 percent in the analysis [https://finance.yahoo.com/markets/stocks/articles/indivior-pharmaceuticals-indv-could-30-021141779.html]. This piece also observes that while the stock's short-term momentum has cooled, with a one-month share price return of negative 8.85 percent, the one-year total shareholder return of 51.60 percent still speaks to strong longer-term performance, suggesting that recent price weakness may be seen as a consolidation phase after a substantial rally [https://finance.yahoo.com/markets/stocks/articles/indivior-pharmaceuticals-indv-could-30-021141779.html]. The interplay between an elevated sales multiple, a discounted fair-value estimate, and updated EBITDA guidance forms the core of the current valuation debate around Indivior.
Sublocade as a growth driver
Sublocade remains central to Indivior's growth story, with the second-quarter 2026 report showing revenues of $253 million, up 21 percent year over year, and U.S. dispense volume climbing 18 percent over the same period [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. The fact that new patient starts reached 32,816 in Q2 2026 underscores that the product is still gaining adoption among people with opioid use disorder, which is critical for sustaining long-term revenue growth and for reinforcing the clinical and societal impact of Indivior's portfolio [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. The improved operating metrics, including a 33 percent year-over-year reduction in adjusted operating expenses to $112 million and a 111 percent surge in adjusted EBITDA to $186 million in the quarter, show that Sublocade’s growth is being leveraged into significantly higher profitability [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ].
For Indivior, maintaining this momentum in Sublocade while integrating a broader CNS pipeline from the proposed Supernus merger could be key to achieving and potentially surpassing the raised 2026 adjusted EBITDA range of $700 million to $740 million, as highlighted in the company’s updated outlook discussion on August 21, 2026 [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689]. If the combination delivers on the pro forma expectations of $2.2 billion in annual revenues and $888 million in adjusted EBITDA, the merged entity would have a substantially larger base of recurring cash flows, which might support further investment in innovation, debt reduction, or shareholder returns over time [https://finance.yahoo.com/healthcare/articles/indiviors-supernus-merger-could-broaden-164000641.html]. Investors will be watching both the trajectory of Sublocade’s adoption and the regulatory and shareholder milestones for the merger as key indicators of whether Indivior can convert its current operational gains into durable value creation.
Sublocade as a representative product
Sublocade, Indivior's long-acting injectable formulation of buprenorphine for the treatment of moderate to severe opioid use disorder, is a key representative product in the company's portfolio and a major contributor to its financial performance in 2026. The Q2 2026 analysis shows that Sublocade generated $253 million in revenue during the quarter, marking a 21 percent increase compared with the same period a year earlier, with U.S. dispense volumes up 18 percent and new patient starts reaching a record 32,816 [https://www.msn.com/en-us/money/economy/should-investors-buy-indv-as-sublocade-growth-meets-rising-risks/ar-AA2aELYJ]. This combination of revenue growth, higher dispense volume, and expanding patient starts illustrates how Sublocade is deepening its penetration in the opioid use disorder treatment market while reinforcing Indivior's strategic emphasis on long-acting injectable therapies.
Indivior stock price context
Indivior stock, represented by the ticker INDV on its ADR listing, most recently shows a previous close at $11.73 with an open at $11.58 and an intraday range between $11.37 and $11.65 as evidenced by a quote page updated on August 22, 2026 [https://ca.finance.yahoo.com/quote/INDV/]. Another contemporaneous narrative references a share price of $36.87 with a one-month return of negative 8.85 percent and a one-year total shareholder return of 51.60 percent, highlighting that while short-term momentum has softened, longer-term investors have still seen substantial gains [https://finance.yahoo.com/markets/stocks/articles/indivior-pharmaceuticals-indv-could-30-021141779.html]. Against this backdrop, a fair-value assessment at $53.00 implies that the shares trade at a discount to one modeled estimate even as other metrics, such as a 3.29 times forward 12-month sales multiple compared with 2.02 times for the peer group, suggest a premium valuation versus peers and the company's own five-year median of 2.7 times [https://www.ad-hoc-news.de/boerse/news/corporate-news/indivior-stock-gains-new-growth-option-with-proposed-supernus-merger-and/69983689].
Read more
More on Indivior stock and company information
Fact box
Key data on Indivior
Company: Indivior Plc
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: Nasdaq (ADR)
